Abbott Laboratories (ABT)

42.98
NYSE : Health Care
Prev Close 42.84
Day Low/High 42.09 / 43.28
52 Wk Low/High 36.00 / 46.63
Avg Volume 10.24M
Exchange NYSE
Shares Outstanding 1.47B
Market Cap 62.97B
EPS 2.90
P/E Ratio 32.95
Div & Yield 1.04 (2.40%)

Latest News

Why Abbott Laboratories (ABT) Stock Is Up Today

Why Abbott Laboratories (ABT) Stock Is Up Today

Abbott Laboratories (ABT) stock was increasing Thursday afternoon as Muddy Waters attempts to break up the company's proposed acquisition of St. Jude (STJ).

Analysts' Actions -- Abbott Labs, Garmin, Nordson, NetApp and More

Analysts' Actions -- Abbott Labs, Garmin, Nordson, NetApp and More

Here are Wednesday's top research calls, including upgrades for Abbott Labs and NetApp, and downgrades for Garmin and Nordsom.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, AXLL, BOKF, FLY, KCAP, RWC Downgrades: BBRG, CCOI, DL, EMG, FLO, HWBK, IIJI, INOD, MTH, NOA, SMCI, SNY, TGNA Initiations: BUFF, GI, NSA Read on to get TheStreet Quant Ratings' detailed report:

This High-Quality Dividend Stock Belongs in Your Portfolio Now

This High-Quality Dividend Stock Belongs in Your Portfolio Now

Abbott Laboratories (ABT) has great growth prospects and has paid increasing dividends for more than 40 years. Here's why this Dividend Aristocrat should be in your investment portfolio.

Abbott Laboratories (ABT) Stock Declines, Alere Deal Looks Uncertain

Abbott Laboratories (ABT) Stock Declines, Alere Deal Looks Uncertain

Abbott Laboratories (ABT) said Alere (ALR) hasn't disclosed key information, making the company question whether its proposed $5.8 billion deal will close.

Insiders Love These 5 Stocks Right Now

Insiders Love These 5 Stocks Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the health services industry higher today.

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Top 10 Dividend Aristocrats to Buy at a Discount Now

Top 10 Dividend Aristocrats to Buy at a Discount Now

These 10 dividend aristocrat stocks offer an average high yield of 3% and have increased dividends for 46 consecutive years on average.

Abbott Laboratories Moves Up In Analyst Rankings, Passing Simon Property Group

Abbott Laboratories Moves Up In Analyst Rankings, Passing Simon Property Group

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #84 spot from Simon Property Group, Inc. , according to ETF Channel.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Abbott Labs (ABT) Stock Price Target Raised at Barclays

Abbott Labs (ABT) Stock Price Target Raised at Barclays

Abbott’s (ABT) stock price target was increased to $50 from $48 at Barclays following the company’s 2016 second quarter results.

Abbott's Alere Deal Continues To Face Uncertainty

Abbott's Alere Deal Continues To Face Uncertainty

The medical device company has two pending acquisitions worth just under $40 billion combined.

St. Jude Medical Up Slightly as It Meets Estimates

St. Jude Medical Up Slightly as It Meets Estimates

The company reported flat but in line earnings of $1.06 per share.

Abbott Labs (ABT) Stock Rising on Q2 Earnings Beat

Abbott Labs (ABT) Stock Rising on Q2 Earnings Beat

Abbott Labs (ABT) 2016 second quarter results surpassed analysts’ expectations.

Trade-Ideas: Abbott Laboratories (ABT) Is Today's Post-Market Leader Stock

Trade-Ideas: Abbott Laboratories (ABT) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Abbott Laboratories (ABT) as a post-market leader candidate

Abbott Labs (ABT) Stock Falling Ahead of Q2 Earnings Report

Abbott Labs (ABT) Stock Falling Ahead of Q2 Earnings Report

Abbott Labs (ABT) will report 2016 second quarter earnings on Wednesday, July 20 before the market opens.

How to Profit From Abbott Labs

How to Profit From Abbott Labs

Abbott Labs -- with its 2.5% dividend yield and market underperformance -- will look safer when the market begins to rotate out of hotter stocks.

5 Big Medtech Stocks Investors Love Right Now -- but Should You Buy Them?

5 Big Medtech Stocks Investors Love Right Now -- but Should You Buy Them?

Can medical technology stocks continue their momentum higher in the second half of the year? Investors say yes, but technical analysis says not necessarily.

What to Look for When Abbott Labs (ABT) Reports Q2 Earnings

What to Look for When Abbott Labs (ABT) Reports Q2 Earnings

Abbott Labs (ABT) is scheduled to report 2016 second-quarter financial results before the market open on Wednesday.

Jim Cramer's 'Mad Money' Recap: Watch for Earnings, Opportunities Next Week

Jim Cramer's 'Mad Money' Recap: Watch for Earnings, Opportunities Next Week

Jim Cramer will be watching a host of earnings next week. In addition, he offers his playbook for financial literacy.

Analyst Sees No Major Concerns on Regulatory Front for Abbott-St. Jude Medical Deal

Analyst Sees No Major Concerns on Regulatory Front for Abbott-St. Jude Medical Deal

Wedbush analyst Tao Levy also does not expect to see rival offers to emerge for St. Jude Medical.

FDA Approves The Tecnis Symfony® Intraocular Lenses, The First And Only Extended Depth Of Focus Lenses For People With Cataracts

FDA Approves The Tecnis Symfony® Intraocular Lenses, The First And Only Extended Depth Of Focus Lenses For People With Cataracts

- Approval includes Toric version of Symfony IOL for people with astigmatism

3 Drugs Stocks Dragging The Industry Down

3 Drugs Stocks Dragging The Industry Down

TheStreet highlights 3 stocks pushing the health services industry lower today.

Abbott Labs (ABT) Stock Gaining on Absorbable Stent Effectiveness

Abbott Labs (ABT) Stock Gaining on Absorbable Stent Effectiveness

Abbott Labs (ABT) absorbable stent, which was approved by the FDA last week, has gone into its first patients.

Trending Tickers: SWN, ABT, AAL, UAL, EW

Oil began to rebound Wednesday from steep declines earlier this week.